Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists

Journal of Medicinal Chemistry

Volumn 43, Issue 11, 2000, Pages 2196-2203

  Jacobson, Kenneth A ^a,c   Ji, Xiao Duo ^a   Li, An Hu ^a   Melman, Neli ^a   Siddiqui, Maqbool A ^b   Shin, Kye Jung ^b   Marquez, Victor E ^b   Ravi, R Gnana ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (HYDROXYMETHYL) 4 [6 [(3 IODOPHENYLMETHYL)AMINO]PURIN 9 YL]BICYCLO[3.1.0]HEXANE 2,3 DIOL; 4 [2 CHLORO 6 [(3 IODOPHENYLMETHYL)AMINO]PURIN 9 YL] 1 (HYDROXYMETHYL)BICYCLO[3.1.0] HEXANE 2,3 DIOL; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR STIMULATING AGENT; ARISTEROMYCIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PURINE NUCLEOSIDE; PURINE RECEPTOR; RIBOSE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; NONHUMAN;

ANIMALS; CELL MEMBRANE; CHO CELLS; CRICETINAE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; PURINE NUCLEOSIDES; RADIOLIGAND ASSAY; RATS; RECEPTORS, PURINERGIC P1; SULFUR RADIOISOTOPES;

EID: 0034212620     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9905965     Document Type: Article

References (41)

1. Jacobson, K. A.; Knutsen, L. J. S. P1 and P2 purine and pyrimidine receptors. Handbook of Experimental Pharmacology; Abbracchio, M. P., Williams, M., Ed., in press.
2. Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto G. A1 and A3 adenosine receptor agonists: An overview. Exp. Opin. Therap. Patents 1999, 9, 515-527.
3. 1-adenosine receptor agonist in guinea pig isolated heart. J. Pharmacol. Exp. Ther. 1994, 271, 1371-1382.
4. Sawynok, J. Adenosine receptor activation and nociception. Eur. J. Pharmacol. 1998, 347, 1-11.
5. 1 receptor agonists with differing lipophilicity in rats: Comparison of pharmacokinetic, hemodynamic and EEG effects. Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 356, 827-837.
6. Wagner, H.; Milavec-Krizman, M.; Gadient, F.; Menninger, K.; Schoeffter, P.; Tapparelli, C.; Pfannkuche, H.-J.; Fozard, J. R. General pharmacology of SDZ WAG 994, a potent selective and orally active adenosine AI receptor agonist. Drug Dev. Res. 1995, 34, 276-288.
7. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 1994, 263, 59-67.
8. 3 receptors during prolonged stimulated ischemia. Am. J. Physiol. 1997, 273, H501-H505.
9. 1-mediated hemodynamic effects. J. Pharmacol. Exp. Ther. 1994, 265, 1506-1511.
10. Dixon, D. A.; Fenix, L. A.; Kim, D. M.; Raffa, R. B. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann. Pharmacother. 1999, 33, 480-488.
11. Dunham, E. W.; Vince, R. Hypotensive and renal vasodilator effects of carbocyclic adenosine (aristeromycin) in anesthetized spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 1986, 238, 954-959.
12. Balwierczak, J. L.; Krulan, C. M.; Wang, Z. C.; Chen, J.; Jeng, A. Y. Effects of adenosine A2 receptor agonists on nucleoside transport. J. Pharmacol. Exp. Ther. 1989, 251, 279-287.
13. McVey, M. J.; Smits, G. J.; Cox, B. F.; Kitzen, J. M.; Clark, K. L.; Perrone, M. H. Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: Coronary hemodynamic and cardioprotective effects in the canine myocardium. J. Cardiovasc. Pharmacol. 1999, 33, 703-710.
14. Siddiqi, S. M.; Jacobson, K. A.; Esker, J. L.; Melman, N.; Tiwari, K. N.; Secrist, J. A.; Schneller, S. W.; Cristalli, G.; Johnson, C. A.; IJzerman, A. P. Search for new purine-and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J. Med. Chem. 1995, 38, 1174-1188.
15. Bradshaw, M.; Rutherford, M. S.; Hoeper, B. J.; McWhinney, C. D.; Borcherding, D. R.; Schook, L. B.; Edwards, C. K., III Specific transcriptional inhibition of bone marrow-derived macrophage tumor necrosis factor-alpha gene expression and protein production using novel enantiomeric carbocyclic nucleoside analogues. J. Pharmacol. Exp. Ther. 1995, 273, 1506-1518.
16. McWhinney, C. D.; Dudley, M. W.; Bowlin, T. L.; Peet, N. P.; Schook, L.; Bradshaw, M.; De, M.; Borcherding, D. R.; Edwards, C. K., III Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur. J. Pharmacol. 1996, 310, 209-216.
17. Rodriguez, J. B.; Marquez, V. E.; Nicklaus, M. C.; Mitsuya, H.; Barchi, J. J., Jr. Conformationally locked nucleoside analogues. Synthesis of dideoxycarbocyclic nucleoside analogues structurally related to neplanocin C. J. Med. Chem. 1994, 37, 3389-3399.
18. Jeong, L. S.; Marquez, V. E.; Yuan, C.-S.; Borchardt, R. T. 4′,1′a-Methanocarbocyclic adenosine analogues as potential inhibitors of S-adenosylhomocysteine hydrolase. Heterocycles 1995, 41, 2651-2656.
19. Marquez, V. E.; Siddiqui, M. A.; Ezzitouni, A.; Russ, P.; Wang, J.; Wagner, R. W.; Matteucci, M. D. Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? J. Med. Chem. 1996, 39, 3739-3747.
20. Ezzitouni, A.; Russ, P.; Marquez, V. E. (1S, 2R)-[(Benzyloxy)-methyl]cyclopent-3-enol. A versatile synthon for the preparation of 4′,1′a-metnano and 1′,1′a-methano carbocyclic nucleosides. J. Org. Chem. 1997, 62, 4870-4873.
21. Marquez, V. E.; Ezzitouni, A.; Russ, P.; Siddiqui, M. A.; Ford, Jr.; H.; Feldman, R. J.; Mitsuya, H.; George, C.; Barchi, J. J., Jr. HIV-1 Reverse Transcriptase Can Discriminate Between Two Conformationally Locked Carbocyclic AZT triphosphate Analogues. J. Am. Chem. Soc. 1998, 720, 2780-2789.
22. Marquez, V. E.; Russ, P.; Alonso, R.; Siddiqui, M. A.; Shin, K. J.; George, C.; Nicklaus, M.; Dai, F.; Ford, H., Jr. Conformationally restricted nucleosides. The reaction of adenosine deaminase with substrates built on a bicyclo[3.1.0]hexane template. Nucleosides Nucleotides 1999, 18, 521-530.
23. Shin, K. J.; Moon, H. R.; George, C.; Marquez, V. E. Construction of the bicyclo[3.1.0]hexane template of a Conformationally locked carbocyclic adenosine via an olefin ketocarbene cycloaddition. J. Org. Chem. 2000, 65, 2172-2178.
24. 3 adenosine receptors: Novel ligands and paradoxical effects. Trends Pharmacol. Sci. 1998, 19, 184-191.
25. 3-selective adenosine agonists. J. Med. Chem. 1994, 37, 636-646.
26. 3-adenosine receptors. J. Med. Chem. 1994, 37, 3614-3621.
27. 2B adenosine receptors. Drug Design Discov. 1999,16, 217-226.
28. 1 adenosine receptor with receptor/G protein complexes in rat-brain membranes. Mol. Pharmacol. 1996, 49, 915-926.
29. 3 adenosine receptor-selective antagonists. Neuropharmacology 1997, 9, 1157-1165.
30. 3 adenosine agonists. Bioorg. Med. Chem. 1995, 3, 1331-1343.
31. van der Wenden, E. M.; Carnielli, M.; Roelen, H. C. P. F.; Lorenzen, A.; von Frijtag Drabbe Künzel, J. K.; IJzerman, A. P. 5′-Substituted adenosine analogues as new high-affinity partial agonists for the adenosine A1 receptor. J. Med. Chem. 1998, 41, 102-108.
32. Kenakin, T. Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci. 1997, 18, 456-464.
33. Yang, Q.; Lanier, S. M. Influence of G protein type on agonist efficacy. Mol. Pharmacol. 1999, 56, 651-656.
34. Clark, R. B.; Knoll, B. J.; Barber, R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol. Sci. 1999, 20, 279-286.
35. Pilla, M.; Perachon, S.; Sautel, F.; Garrido, F.; Mann, A.; Wermuth, C. G.; Schwartz, J.-C.; Everitt, B. J.; Sokoloff, P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999, 400, 371-375.
36. 1 receptor ligands. J. Med. Chem. 2000, 43, 829-842.
37. Franchetti, P.; Cappellacci L.; Marchetti, S.; Trincavelli, L.; Martini, C.; Mazzoni, M. R.; Lucacchini, A.; Grifantini, M. 2′-C-Methyl analogues of selective adenosine receptor agonists: Synthesis and binding studies. J. Med. Chem. 1998, 41, 1708-1715.
38. 1 receptor: Molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J. Med. Chem. 1998, 41, 1456-1466.
39. Altona, C.; Sundaranlingam, M. Conformational Analysis of the Sugar Ring in Nucleosides and Nucleotides. A New Description Using the Concept of Pseudorotation. J. Am. Chem. Soc. 1972, 94, 8205-8212.
40. Saenger, W. Principles of Nucleic Acid Structure; Springer-Verlag: New York, 1984.
41. 3 adenosine receptors: design of selective ligands and therapeutic prospects. Drugs Future 1995, 20, 689-699.